CS
RVNC

Credit Suisse’s Revance Therapeutics, Inc. RVNC Stock Holding History

Credit Suisse’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$886K Buy
180,148
+8,141
+5% +$48.2K ﹤0.01% 2337
2023
Q4 		$1.51M Buy
172,007
+31,392
+22% +$257K ﹤0.01% 2070
2023
Q3 		$1.61M Sell
140,615
-1,573
-1% -$30.2K ﹤0.01% 1965
2023
Q2 		$3.6M Buy
142,188
+3,342
+2% +$104K ﹤0.01% 1552
2023
Q1 		$4.47M Buy
138,846
+8,841
+7% +$276K ﹤0.01% 1397
2022
Q4 		$2.4M Buy
130,005
+32,752
+34% +$749K ﹤0.01% 1771
2022
Q3 		$2.63M Buy
97,253
+6,376
+7% +$129K ﹤0.01% 1667
2022
Q2 		$1.25M Buy
90,877
+224
+0.2% +$3.45K ﹤0.01% 2232
2022
Q1 		$1.77M Buy
90,653
+5,683
+7% +$86.2K ﹤0.01% 2172
2021
Q4 		$1.39M Sell
84,970
-1,086
-1% -$18.1K ﹤0.01% 3063
2021
Q3 		$2.4M Buy
86,056
+3,761
+5% +$107K ﹤0.01% 2684
2021
Q2 		$2.44M Sell
82,295
-3,607
-4% -$104K ﹤0.01% 2709
2021
Q1 		$2.4M Sell
85,902
-21,598
-20% -$597K ﹤0.01% 2679
2020
Q4 		$3.05M Buy
107,500
+51,109
+91% +$1.32M ﹤0.01% 2507
2020
Q3 		$1.42M Buy
56,391
+6,927
+14% +$182K ﹤0.01% 2682
2020
Q2 		$1.21M Sell
49,464
-10,076
-17% -$199K ﹤0.01% 2766
2020
Q1 		$881K Buy
59,540
+24,528
+70% +$507K ﹤0.01% 2757
2019
Q4 		$568K Buy
35,012
+7,967
+29% +$124K ﹤0.01% 3491
2019
Q3 		$352K Sell
27,045
-1,962
-7% -$24K ﹤0.01% 3621
2019
Q2 		$376K Buy
29,007
+5,378
+23% +$67.8K ﹤0.01% 3565
2019
Q1 		$373K Buy
23,629
+3,849
+19% +$66.7K ﹤0.01% 3495
2018
Q4 		$398K Buy
19,780
+2,462
+14% +$54.2K ﹤0.01% 3378
2018
Q3 		$431K Sell
17,318
-7,491
-30% -$204K ﹤0.01% 3379
2018
Q2 		$682K Sell
24,809
-766
-3% -$23K ﹤0.01% 3273
2018
Q1 		$788K Sell
25,575
-2,491
-9% -$80.1K ﹤0.01% 3122
2017
Q4 		$1M Buy
28,066
+3,693
+15% +$106K ﹤0.01% 2991
2017
Q3 		$670K Buy
24,373
+11,767
+93% +$285K ﹤0.01% 3369
2017
Q2 		$332K Sell
12,606
-560
-4% -$12.5K ﹤0.01% 3404
2017
Q1 		$274K Sell
13,166
-4,912
-27% -$101K ﹤0.01% 3546
2016
Q4 		$374K Sell
18,078
-4,808
-21% -$80.5K ﹤0.01% 3570
2016
Q3 		$371K Sell
22,886
-1,966
-8% -$28.5K ﹤0.01% 3573
2016
Q2 		$338K Sell
24,852
-14,431
-37% -$255K ﹤0.01% 3644
2016
Q1 		$685K Buy
39,283
+22,477
+134% +$457K ﹤0.01% 3009
2015
Q4 		$574K Buy
16,806
+2,345
+16% +$81.3K ﹤0.01% 3269
2015
Q3 		$430K Sell
14,461
-22,637
-61% -$688K ﹤0.01% 3503
2015
Q2 		$1.19M Buy
37,098
+11,604
+46% +$298K ﹤0.01% 3012
2015
Q1 		$529K Sell
25,494
-11,914
-32% -$206K ﹤0.01% 3509
2014
Q4 		$633K Buy
37,408
+18,935
+103% +$331K ﹤0.01% 3535
2014
Q3 		$357K Buy
18,473
+11,407
+161% +$297K ﹤0.01% 3838
2014
Q2 		$240K Buy
+7,066
New +$221K ﹤0.01% 4242

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's RVNC Position: Q1 2024 in Review

Credit Suisse increased its Revance Therapeutics, Inc. (RVNC) stake by 4.7% in Q1 2024, buying an estimated $48.2K and bringing the position to 180,148 shares worth $886K. The position accounts for ﹤0.01% of the portfolio, ranked #2337.

Credit Suisse first reported a position in RVNC in Q2 2014 and has held it in 40 quarters since. The position peaked at $4.47M in Q1 2023. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

  • Credit Suisse held 180,148 shares of Revance Therapeutics, Inc. worth $886K as of Q1 2024.
  • Credit Suisse bought 8,141 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $48.2K.
  • Revance Therapeutics, Inc. made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2337 holding.
  • Credit Suisse first reported a position in Revance Therapeutics, Inc. in Q2 2014 and has held it in 40 quarters since.
  • Credit Suisse's Revance Therapeutics, Inc. position peaked at $4.47M in Q1 2023.
  • 188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.